Objective: To analyze the clinical data of different pathological types of uterine sarcoma. Methods: From May 2016 to April 2019, 15 patients with uterine sarcoma were treated in the Gynecology Department of the First Affiliated Hospital of University of Science and Technology of China. Clinical features, age, menopausal time, preoperative laboratory, imaging examination, operation and postoperative follow-up were analyzed retrospectively. Results: 1) The average age of uterine leiomyosarcoma patients was (56.38±10.24) years old; the size of the mass was (91.75±52.37) mm, carbohydrate antigen 125 (CA125) (31.9±21.81) U/mL, lactate dehydrogenase (LDH) (222.68±146.58) U/L. After surgery, 2 patients received chemoradiotherapy; 4 received chemotherapy; and metastasis occurred in 3 patients during follow-up. 2) The average age of patients with endometrial stromal sarcoma was (58.40±13.35) years old; the size of the mass was (92.60±23.11) mm, CA125 (25.00±13.04) U/mL, LDH (237.60±78.72) U/L. One patient received chemotherapy and radiotherapy, and one patient received chemotherapy. All patients survived during follow-up. 3) The average age of uterine adenosarcoma patients was 42 years old; the mass size was 75 mm, CA125 39.63 U/mL, and LDH 163 U/L. All patients received chemotherapy after surgery. One patient died during follow-up. Conclusion: Patients with uterine sarcoma are mostly treated with pelvic mass and vaginal bleeding. LDH >199 U/L and pelvic mass ≥8 cm in diameter, the rapid growth of mass can be used as distinguishing indicators. It is unclear whether lymph node dissection has benefited patients during surgery, and it is worth studying whether the lymph node metastasis is evaluated before surgery. Although uterine sarcoma occurs in perimenopausal and menopausal women, for young women with pelvic mass and vaginal bleeding, the possibility of uterine adenosarcoma should be considered to avoid worsening the patient condition.